Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides anthelmintics, pet vaccines, ear canal treatment drugs, anesthetic analgesics, antibiotics, antivirals, various internal medicine drugs, as well as disinfectant products, i… Read more
Tianjin Ringpu Bio Tech (300119) - Total Assets
Latest total assets as of September 2025: CN¥7.69 Billion CNY
Based on the latest financial reports, Tianjin Ringpu Bio Tech (300119) holds total assets worth CN¥7.69 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tianjin Ringpu Bio Tech - Total Assets Trend (2007–2024)
This chart illustrates how Tianjin Ringpu Bio Tech’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tianjin Ringpu Bio Tech - Asset Composition Analysis
Current Asset Composition (December 2024)
Tianjin Ringpu Bio Tech's total assets of CN¥7.69 Billion consist of 45.8% current assets and 54.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.1% |
| Accounts Receivable | CN¥1.14 Billion | 14.3% |
| Inventory | CN¥499.57 Million | 6.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥686.14 Million | 8.6% |
| Goodwill | CN¥442.26 Million | 5.6% |
Asset Composition Trend (2007–2024)
This chart illustrates how Tianjin Ringpu Bio Tech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Ringpu Bio Tech's current assets represent 45.8% of total assets in 2024, a decrease from 62.5% in 2007.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2024, down from 25.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 7.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 14.3% of total assets.
Tianjin Ringpu Bio Tech Competitors by Total Assets
Key competitors of Tianjin Ringpu Bio Tech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Tianjin Ringpu Bio Tech - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tianjin Ringpu Bio Tech generates 0.39x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Tianjin Ringpu Bio Tech generates $ 3.78 in net profit.
Tianjin Ringpu Bio Tech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.08 | 1.92 | 1.83 |
| Quick Ratio | 1.79 | 1.70 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.88 Billion | CN¥ 1.61 Billion | CN¥ 727.57 Million |
Tianjin Ringpu Bio Tech - Advanced Valuation Insights
This section examines the relationship between Tianjin Ringpu Bio Tech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.88 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 20.8% |
| Total Assets | CN¥7.97 Billion |
| Market Capitalization | $621.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Ringpu Bio Tech's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tianjin Ringpu Bio Tech's assets grew by 20.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tianjin Ringpu Bio Tech (2007–2024)
The table below shows the annual total assets of Tianjin Ringpu Bio Tech from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.97 Billion | +20.77% |
| 2023-12-31 | CN¥6.60 Billion | +8.02% |
| 2022-12-31 | CN¥6.11 Billion | +7.30% |
| 2021-12-31 | CN¥5.69 Billion | +45.95% |
| 2020-12-31 | CN¥3.90 Billion | +9.43% |
| 2019-12-31 | CN¥3.56 Billion | +18.84% |
| 2018-12-31 | CN¥3.00 Billion | +2.54% |
| 2017-12-31 | CN¥2.92 Billion | +6.99% |
| 2016-12-31 | CN¥2.73 Billion | +16.37% |
| 2015-12-31 | CN¥2.35 Billion | +18.44% |
| 2014-12-31 | CN¥1.98 Billion | -1.01% |
| 2013-12-31 | CN¥2.00 Billion | +11.70% |
| 2012-12-31 | CN¥1.79 Billion | +7.31% |
| 2011-12-31 | CN¥1.67 Billion | +3.01% |
| 2010-12-31 | CN¥1.62 Billion | +290.84% |
| 2009-12-31 | CN¥415.11 Million | +23.86% |
| 2008-12-31 | CN¥335.15 Million | +79.74% |
| 2007-12-31 | CN¥186.46 Million | -- |